Combination Therapy of TGF-β Blockade and Commensal-derived Probiotics Provides Enhanced Antitumor Immune Response and Tumor Suppression
Open accessThe DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Galunisertib (Gal) is a transforming growth factor (TGF-β) blockade which is being investigated as a potential tumor immunotherapy candidate drug in clinical trials.However, primary or acquired resistance is often found in the recruited cancer patients, which limits its clinical application.Tumor immune microenvironment can be regulated by intestinal microbiota, leading to different therapeutic outcomes.It is hypothesized that manipulation of cancer patients' intestinal microbiome in the early stage of therapy may be a promising strategy to improve the therapeutic efficacy of Gal.Methods: 4T1 and H22 subcutaneous tumor bearing mice were used to evaluate the therapeutic effect.Escherichia coli strain Nissle 1917 (EcN), a widely used probiotic bacteria, was orally delivered to the tumor bearing mice daily along with Gal treatment.Antitumor effect of the combination therapy was evaluated by tumor volume, histological staining of tumor tissues.Furthermore, flow cytometry was performed to analyze the alteration of immune microenvironment in tumor bed after treatment.The suppressing effect of the combination therapy on tumor invasiveness and metastasis was evaluated in both mice and zebrafish xenografts models.Fecal sample 16S rRNA gene sequencing was conducted to analyze changes of intestinal microbial diversity.The effect of intestinal microbiota on tumor suppression after receiving EcN was further tested by fecal transplant.Results: The therapeutic outcomes in tumor growth inhibition and metastasis suppression of Gal were significantly potentiated by EcN, resulting from the strengthened antitumor immunity.EcN was able to relieve the immunosuppressive tumor microenvironment, which was evidenced by enhanced tumor-specific effector T cells infiltration and dendritic cells activation.Intestinal microbiota was modulated by EcN, illustrated by a shift of gut microbiome toward certain beneficial bacteria.Conclusion: These results suggested that Gal combined with EcN might be a novel therapeutic approach with great potential of clinical implications for cancer prevention or treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Microenvironmental regulation of tumor progression and metastasis
Quail, D. F., & Joyce, J. A. (2013) · Nature Medicine · doi:10.1038/nm.3394 · Cited by 7,994 · cited 13×
“Importantly, administration of TGF-β blockade with EcN resulted in a significant improvement in the subcutaneous TME, demonstrated by a significant reduction in the level of immuno-inhibitory cytokines such as TGF-β and IL-10 both in the serum and tumor tissue homogenate (Figure 3F-H).”
BackgroundInfluentialGut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Routy, B., Le Chatelier, E., Derosa, L., Duong, C. P. M., Alou, M. T., Daillère, R., Fluckiger, A., Messaoudene, M., Rauber, C., Roberti, M. P., et al. (2018) · Science · doi:10.1126/science.aan3706 · Cited by 5,671
Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease
Wang, Z., Klipfell, E., Bennett, B. J., Koeth, R., Levison, B. S., DuGar, B., Feldstein, A. E., Britt, E. B., Fu, X., Chung, Y.-M., et al. (2011) · Nature · doi:10.1038/nature09922 · Cited by 5,597 · cited 1×
“2 g/L) in their drinking water for 1 week [24].”
BackgroundCommensal Bifidobacterium promotes antitumor immunity and facilitates anti–PD-L1 efficacy
Sivan, A., Corrales, L., Hubert, N., Williams, J. B., Aquino-Michaels, K., Earley, Z. M., Benyamin, F. W., Man Lei, Y., Jabri, B., Alegre, M.-L., et al. (2015) · Science · doi:10.1126/science.aac4255 · Cited by 3,888 · cited 1×
“Notably, single dose with Bifidobacterium on 7th and 14th days after tumor implantation could protect against tumor initiation as effective as anti PD-L1 therapy, shedding light on the non-negligible role of specific commensal bacteria in tumor control [37].”
BackgroundAnticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488 · cited 2×
“Bacteria within the Bacteroides in general, or specifically, Bacteroides thetaiotaomicron and Bacteroides fragilis were identified as the responsible mediator of anti-CTLA-4 therapy through inducting a Th1 immune response [19].”
BackgroundTumor mutational burden and response rate to PD-1 inhibition
Yarchoan, M., Hopkins, A., & Jaffee, E. M. (2017) · New England Journal of Medicine · doi:10.1056/nejmc1713444 · Cited by 3,230 · cited 14×
“Importantly, administration of TGF-β blockade with EcN resulted in a significant improvement in the subcutaneous TME, demonstrated by a significant reduction in the level of immuno-inhibitory cytokines such as TGF-β and IL-10 both in the serum and tumor tissue homogenate (Figure 3F-H).”
BackgroundInfluentialThe tumor microenvironment and its role in promoting tumor growth
Whiteside, T. L. (2008) · Oncogene · doi:10.1038/onc.2008.271 · Cited by 2,376 · cited 1×
“obtained from human tumor tissues showed inhibited proliferation in response to tumor antigens, compromised signaling through T cell receptors and decreased ability to mediate cytotoxicity of tumor targets [33].”
BackgroundTGF-β Signaling in Tumor Suppression and Cancer Progression
Derynck, R., Akhurst, R. J., & Balmain, A. (2001) · Nature Genetics · doi:10.1038/ng1001-117 · Cited by 2,275
The Intestinal Microbiota Modulates the Anticancer Immune Effects of Cyclophosphamide
Viaud, S., Saccheri, F., Mignot, G., Yamazaki, T., Daillère, R., Hannani, D., Enot, D. P., Pfirschke, C., Engblom, C., Pittet, M. J., et al. (2013) · Science · doi:10.1126/science.1240537 · Cited by 2,050
Schwabe, R. F., & Jobin, C. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3610 · Cited by 1,689
Targeting the TGFβ signalling pathway in disease
Akhurst, R. J., & Hata, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3810 · Cited by 1,466
Chaput, N., Lepage, P., Coutzac, C., Soularue, E., Le Roux, K., Monot, C., Boselli, L., Routier, E., Cassard, L., Collins, M., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx108 · Cited by 1,310
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
The gut microbiota influences anticancer immunosurveillance and general health
Routy, B., Gopalakrishnan, V., Daillère, R., Zitvogel, L., Wargo, J. A., & Kroemer, G. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-018-0006-2 · Cited by 523
Sonnenborn, U. (2016) · FEMS Microbiology Letters · doi:10.1093/femsle/fnw212 · Cited by 315 · cited 1×
“Escherichia coli strain Nissle 1917 (EcN), a most investigated versatile commensal bacteria with strain specific properties and proven efficacy, has been successfully used to treat chronic inflammatory disorders and strengthen the gut barrier functions in clinical applications [20, 21].”
BackgroundLactobacillus rhamnosus GG: An Overview to Explore the Rationale of Its Use in Cancer
Banna, G. L., Torino, F., Marletta, F., Santagati, M., Salemi, R., Cannarozzo, E., Falzone, L., Ferraù, F., & Libra, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00603 · Cited by 150 · cited 2×
“For example, Lactobacillus rhamnosus GG is well characterized and has been shown to be helpful in anti-cancer therapeutic practice [44].”
BackgroundCarcinogenesis and therapeutics: the microbiota perspective
Tsilimigras, M. C. B., Fodor, A., & Jobin, C. (2017) · Nature Microbiology · doi:10.1038/nmicrobiol.2017.8 · Cited by 144
Cai, S., Kandasamy, M., Rahmat, J. N., Tham, S. M., Bay, B. H., Lee, Y. K., & Mahendran, R. (2016) · Journal of Immunology Research · doi:10.1155/2016/7402760 · Cited by 56 · cited 1×
“In particular, it can stimulate the DCs maturation and modulate T-cells mediated anti-tumor immune response [45].”
Background
Cited by
Liu, Y.-J., Tang, B., Wang, F.-C., Tang, L., Lei, Y.-Y., Luo, Y., Huang, S.-J., Yang, M., Wu, L.-Y., Wang, W., et al. (2020) · Theranostics · doi:10.7150/thno.43716 · Cited by 344
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma
Qian, Y., Gong, Y., Fan, Z., Luo, G., Huang, Q., Deng, S., Cheng, H., Jin, K., Ni, Q., Yu, X., et al. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00958-3 · Cited by 312
The impact of the gut microbiome on tumor immunotherapy: from mechanism to application strategies
Guo, C., Kong, L., Xiao, L., Liu, K., Cui, H., Xin, Q., Gu, X., Jiang, C., & Wu, J. (2023) · Cell & Bioscience · doi:10.1186/s13578-023-01135-y · Cited by 48
Next‐Generation Probiotics: From Traditional Strains to Personalized Therapeutics
Jadhav, N. K., Magdum, A. B., Shinde, K. V., & Nimbalkar, M. S. (2026) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.70339 · Cited by 29
Wu, H., Van Der Pol, W. J., Dubois, L. G., Morrow, C. D., & Tollefsbol, T. O. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24109015 · Cited by 27
“Akkermansia is also a next generation beneficial strain for improving gut health and is known to be positively correlated with IFN-gamma and negatively correlated with immunosuppressive cytokines, thus potentially used to enhance immune response [43,44].”
Background
Metadata
- Authors
- Shi, L., Sheng, J., Wang, M., Luo, H., Zhu, J., Zhang, B., Liu, Z., & Yang, X.
- Venue
- Theranostics
- Publisher
- Ivyspring International Publisher
- Published
- 2019
- Volume
- 9
- Issue
- 14
- Pages
- 4115-4129
- ISSN
- 1838-7640 (ISSN-L)
- OpenAlex
- W2951414333
- Cited by
- 101
- References
- 18
- FWCI
- 7.74
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.